MedTrace Logo

Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM

NCT02334969 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2200

Last updated 2018-11-19

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of Naoxintong Capsule in the secondary prevention of ischemic stroke by the multi-center, randomized,double-blind，placebo-controlled trial design project.

Conditions

Interventions

DRUG

Naoxintong Capsule

This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.

DRUG

Placebo

placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.

Sponsors & Collaborators

  • Shanghai Municipal Science and Technology Commission

    collaborator OTHER_GOV

  • Xiaofei Yu

    lead OTHER

Principal Investigators

  • Xiao F Yu, Doctor · ShuGuang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-08-30
Completion
2018-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02334969 on ClinicalTrials.gov